دورية أكاديمية
أعرض في EDS

Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience

التفاصيل البيبلوغرافية
العنوان: Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience
المؤلفون: Aygen, Bilgehan, Demirtürk, Neşe, Yıldız, Orhan, Çelen, Mustafa Kemal, Çelik, İlhami, Barut, Şener, Ural, Önur, Batırel, Ayşe, Mıstık, Reşit, Şi̇mşek, Funda, Asan, Ali, Ersöz, Gülden Munis, Türker, Nesrin Akbaş, Bilgin, Hüseyin, Kınıklı, Sami, Karakeçili, Faruk, Zararsız, Gökmen, Günal, Özgür, Akhan, Sıla Cetin, Tulek, N., İnan, Dilara, Çaǧatay, Arif Atahan, Gürbüz, Yunus, Şener, Alper, Çelikbaş, Aysel Kocagül, Çetinkaya, Rıza Aytaç, Kadanalı, Ayten, Hakyemez, İsmail Necati, Kuruüzüm, Ziya, Özel, Selcan Arslan, Korkmaz, Pınar Yagiz, Tuna, Nazan, Saltoǧlu, Neşe, Tarakçı, Hüseyin, Uysal, Burcu, Karagöz, Ergenekon, Koçulu, Safiye, Ayaz, Celal, Güzel, Deniz Kamalak, Türkoğlu, Emine, Demir, Nazlım Aktuğ, Şimşek, Sümeyra, Kantürk, Arzu, Akça, Mustafa Özgür, Evik, Güliz, Örmen, Bahar Kopraman, Sili, Uluhan, Hatipoǧlu, Çiǧdem Ataman, Binay, Umut Devrim, Kılıç, Sırrı, Arslan, Kader, Yenilmez, Ercan, Çomoǧlu, Şenol, Koç, Meliha Meriç, Gökgöz, Altan, Dursun, Zehra Beştepe, Sümer, Şua, Heper, Yasemin, Yíldírmak, Taner T., Öztürk, Sinan, Güğül, Tuğba Demirel, Yüce, Zeynep Türe
بيانات النشر: AVES
سنة النشر: 2020
مصطلحات موضوعية: Chronic hepatitis C, Dasabuvir, HCV genotypes 1 and 4, Ombitasvir, Paritaprevir, Real-world effectiveness
الوصف: WOS:000535263200004 ; PMID: 32412901 ; Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r ± DSV ± RBV combination regimen in a real-world clinical practice. Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r ± DSV ± RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed. Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naïve. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%. Conclusion: The present real-life data of Turkey for the OBV/PTV/r ± DSV ± RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. © Copyright 2020 by The Turkish Society of Gastroenterology
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
تدمد: 1300-4948
2148-5607
العلاقة: Turkish Journal of Gastroenterology; Makale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanı; Aygen, B., Demirtürk, N., Yıldız, O., Çelen, M. K., Çelik, İ., Barut, Ş. ve diğerleri. (2020). Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology, 31(4), 305-317.; https://www.turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-the-turkey-experience-experience-136659Test; https://hdl.handle.net/11468/7219Test; 31; 305; 317; WOS:000535263200004; 2-s2.0-85084787334; https://search.trdizin.gov.tr/yayin/detay/419482Test; Q3; Q4
DOI: 10.5152/TJG.2020.19197
الإتاحة: https://doi.org/10.5152/TJG.2020.19197Test
https://hdl.handle.net/11468/7219Test
https://www.turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-the-turkey-experience-experience-136659Test
https://search.trdizin.gov.tr/yayin/detay/419482Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.D03B0E75
قاعدة البيانات: BASE
الوصف
تدمد:13004948
21485607
DOI:10.5152/TJG.2020.19197